TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04302350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide
Description: During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nitrous oxide
Description: During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nitrous oxide
Description: During one-lung ventilation with an open chest, the nonventilated lung collapses initially due to elastic recoil, which quickly brings the lung down to its closing capacity. Remaining gas in the lung is then removed by absorption into the pulmonary capillary blood. The rapid diffusion properties of N2O（Blood gas distribution coefficient is 0.47）would be expected to speed lung collapse and so facilitate surgery. The previous study suggested that increasing the concentration of N2O in mixtures of N2O/O2 will lead to a faster rate of collapse. When using nitrous oxide in oxygen during lung ventilation, ongoing oxygen uptake by blood shunting will serve to increase the partial pressure of nitrous oxide in parts of the lung that are still expanded. This will soon result in a partial pressure gradient for nitrous oxide uptake also, with a consequent faster rate of lung collapse than would occur in a patient being ventilated with 100% oxygen.
Study: NCT03013114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
Study: NCT03364205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution-focused interview technique
Description: This approach helps an individual make decisions about behavioral change, focusing particularly on his or her past achievements and looking forward to a time when the problems cease to exist.
Study: NCT01896297

Intervention type: DRUG
Group type: OTHER
Intervention: Pradaxa, dabigatran etexilate
Description: 75mg BID by oral
Study: NCT04611035

Intervention type: DEVICE
Intervention: QPOP
Description: QPOP will then be applied to establish the most efficacious drug combination for the specific organoid. Additional drugs other than those listed above may be screened depending on availability of cancer organoids. When patients progress after first-line treatment, QPOP generated second-line options will be informed to treating physicians and the physician will exercise his/her discretion to select the most suitable drug based on patient's comorbidities and organ function after a formal molecular/phenotype tumour board.
Study: NCT04376489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants experiencing negative affect & cigarettes are available)
Description: Participants receive messages tailored for situations when they experiencing negative affect \& cigarettes are available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants not experiencing negative affect & cigarettes are available)
Description: Participants receive messages tailored for situations when they cigarettes are available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants experiencing negative affect & cigarettes are not available)
Description: Participants receive messages tailored for situations when they experiencing negative affect.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages (participants not experiencing negative affect & cigarettes are not available)
Description: Generic messages for situations when participants are neither experiencing negative affect nor cigarettes are available.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moodsurf
Description: Smart phone app that teaches participants a mindfulness-based technique in which participant surf the mood.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditate
Description: Smart phone app that teaches participants a mindfulness-based meditation designed for smoking cessation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Joy
Description: Smart phone app that teaches participants to practice breathing exercise.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagine
Description: Smart phone app that teaches participants to use their imagination to explore and manage their thoughts and feelings.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Notice
Description: Smart phone app that teaches participants to accept their thoughts and feelings.
Study: NCT03951428

Intervention type: DIAGNOSTIC_TEST
Intervention: Menstrual Blood Screening Test
Description: The sponsor will be testing women's menstrual blood to investigate the feasibility and efficacy of assessing three early stage cancers via self-collected menstrual blood using FDA approved devices.
Study: NCT04328948

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Chemoradiotherapy
Description: Chemoradiotherapy
Study: NCT03522779

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry Juice
Description: Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry Juice
Description: Tart cherry juice will be used to compare antioxidant and oxidative stress levels in human plasma following a high fat meal.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-fat meal
Description: A high fat meal will be given to elicit postprandial oxidative stress.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: The exercise will consist of 30 minutes of treadmill running at 70% of each participants' calculated heart rate reserve.
Study: NCT00996125

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CervarixTM
Description: Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
Study: NCT03595514

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single injection
Description: Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Double injection
Description: Local anesthetic injection with a mixture of 35 mL of lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone 2 mg, in the middle of the three cords of the brachial plexus as well as at the intersection of the subclavian artery and the medial cord.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine, bupivacaine, epinephrine, dexamethasone
Description: lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine, bupivacaine, epinephrine, dexamethasone
Description: lidocaine 1.0%-bupivacaine 0.25% with epinephrine 5 µ/mL and dexamethasone
Study: NCT03938844

Intervention type: PROCEDURE
Intervention: BURCH Colposuspension
Description: stress urinary incontinence surgery ( burch or tot)

Intervention type: PROCEDURE
Intervention: TOT
Study: NCT03806855

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary

Intervention type: DIAGNOSTIC_TEST
Intervention: Bladder diary
Description: 3-day bladder diary
Study: NCT00980239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Starting dose of 35 mg/m\^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Starting dose 60 mg/m\^2 by vein over 2 hours on Days 1 and 15 of every cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
Study: NCT00026494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study: NCT00665431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400 (VIMOVO)
Description: 500 mg naproxen/20 mg esomeprazole bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celebrex
Description: 200 mg celecoxib qd

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue Antacid
Description: Antacid Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue Antacid
Description: Antacid Tablets
Study: NCT04815811

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood collection
Description: Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood collection
Description: Blood samples collections to evaluation of the potential role of the sex chromosomes in the innate immune response by analyzing inflammatory cytokine production (IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α), studying the cell diapedesis receptor CD99 on PMNs, monocytes, and lymphocytes, analyzing the contribution of X-linked genes of the TLR pathways and the influence of X-linked miRNAs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: Fecal sample collection to delineate microbiome contribution, we will study the gut microbiota in faecal samples obtained from the recruited patients.
Study: NCT02134015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab
Description: Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Oral erlotinib 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Oral erlotinib 150 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo infusion every 3 weeks
Study: NCT00979316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-708163
Description: Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
Study: NCT01732458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Aprepitant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Administered IV at a dose of 4 mg for participants \>40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants \<1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ondansetron
Description: Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ondansetron
Description: Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ondansetron
Description: Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
Study: NCT03962777

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine
Description: patients used chx moutrinses for four days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oil pulling
Description: patients used oil pulling for four days
Study: NCT02087540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 80mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Telmisartan 80mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Rosuvastatin 20mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Rosuvastatin 20mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Rosuvastatin 20mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Rosuvastatin 20mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo(for Rosuvastatin 10mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo(for Rosuvastatin 10mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Rosuvastatin 10mg)
Study: NCT01154114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: darapladib 40 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darapladib
Description: darapladib 40 mg oral dose
Study: NCT03805035

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Group 2 (n=10) EA at ST36 and GB34;intensity (2 mA), pulse width (1 ms), frequency (2 Hz)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihistamine(low dose) chlorpheniramine (Dexchlorpheniramine maleate)
Description: Group 3 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate 2mg/tab, 1 tab);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: antihistamine(high dose) chlorpheniramine (Dexchlorpheniramine maleate)
Description: Group 4 (n=10) EA at ST36 and GB34 plus chlorpheniramine (Dexchlorpheniramine maleate2mg/tab, 2 tabs);intensity (2 mA), pulse width (1 ms), frequency (2 Hz)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: acupuncture
Description: Minimal needling at ST36 and GB34
Study: NCT03494634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 30mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study: NCT02484274

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood samples
Description: 1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
Study: NCT04080388

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung Impedance Device
Description: The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung Impedance Device
Description: The non-invasive lung impedance device enables assessment of the level of pulmonary congestion and can be an indication for additional anti-congestive treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-congestive treatment
Description: Continuation of in-hospital anti-congestive treatment